Autolus Therapeutics' GAAP loss for 9M 2021 was $100.43 million, up 1.2% from $99.233 million in the prior year. Revenue increased 6.2-fold to $1,507 million from $0.242 million a year earlier.
Autolus Therapeutics' GAAP loss for 9M 2021 was $100.43 million, up 1.2% from $99.233 million in the prior year. Revenue increased 6.2-fold to $1,507 million from $0.242 million a year earlier. 
autolus.gcs-web.com
English (US) 